HIV-infected long-term nonprogressors: Epidemiology, mechanisms of delayed progression, and clinical and research implications

Microbes and Infection

Volumn 1, Issue 13, 1999, Pages 1113-1120

  Buchbinder, Susan ^a   Vittinghoff, Eric ^b  

^a HIV Research Section   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cofactors; HIV; Nonprogressor; Progression; Survival

Indexed keywords

CHEMOKINE RECEPTOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOTOXIC T LYMPHOCYTE; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; ETHNOLOGY; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; SEROCONVERSION; VIRUS LOAD; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032701942     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)00204-X     Document Type: Review

References (54)

1. Strathdee S.A., Veugelers P.J., Page-Shafer K.A. Lack of consistency between five definitions of non-progression in cohorts of HIV-infected seroconverters. AIDS. 10:1996;959-965.
2. Petrucci A., Dorrucci M., Alliegro M.B. How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS). J. Acquir. Immun. Defic. Syndr. 14:1997;243-248.
3. Lefrere J.J., Morand-Joubert L., Mariotti M. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 yearsa of human immunodeficiency virus infection. Blood. 90:1997;1133-1140.
4. Buchbinder S.P., Vittinghoff E., Park M.S. Long-term non-progression in the San Francisco City Clinic Cohort. J. Clin. Epidemiol. 47:1994;59-67.
5. Farzadegan H., Hoover D.R., Astemborski J. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 352:1998;1510-1514.
6. Soriano V., Martin R., Del Romero J. Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid. Medicina Clinica. 107:1996;761-766.
7. Prins M., Veugelers P.J. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS. 11:1997;621-631.
8. Prins M., Hernaandez Aguagdo I.H., Brettle R.P., et al. Pre-AIDS mortality from natural casuses associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 11:1997;1747-1756.
9. Vicenzi E., Bagnarelli P., Santagostina E. Hemophilia and non-progressing human immunodeficiency virus type 1 infection. Blood. 89:1997;191-200.
10. Martin N., Koup R., Kaslow R. Workshop on perinatally acquired human immunodeficiency virus infection in long-term surviving children: a collaborative study of factors contributing to slow disease progression. The Long-Term Survivor Project. AIDS Res. Hum. Retroviruses. 12:1996;1565-1570.
11. Hessol N.A., Koblin B.A., Van Griensven G.J.P. Progression of Human Immunodeficiency Virus Type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am. J. Epidemiol. 139:1994;1077-1087.
12. Buchbinder S.P., Katz M.H., Hessol N.A. Long-term HIV-1 infection without immunologic progression. AIDS. 8:1994;1123-1128.
13. +cell counts. J. Infect. Dis. 169:1994;1236-1243.
14. Mellors J.W., Rinaldo Jr C.R., Gupta P. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
15. O'Brien T.R., Blattner W.A., Waters D. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 276:1996;105-110.
16. Hogervorst E., Jurriaans S., DeWolf F. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:1995;811-821.
17. Saksela K., Stevens C.E., Rubinstein P. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann. Intern. M. 123:1995;641-648.
18. Comar M., Simonelli C., Zanussi S. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J. Clin. Invest. 100:1997;893-903.
19. Pantaleo G., Menzo S., Vaccarezza M. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. M. 332:1995;209-216.
20. Learmont J., Geczy A., Raynes-Greenow C. The Sydney BloodBank Cohort infected with attenuated quasi-species of HIV-1: Long-term non-progression. XII World AIDS Conference, Geneva, Switzerland, June 28-July 3. 1998;. Abstract 13350.
21. Mariani R., Kirchhoff F., Greenough T.C. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70:1996;7752-7764.
22. Connor R.I., Sheridan K.E., Lai C. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 70:1996;5306-5311.
23. Wang B., Ge Y.C., Palasanthiran P. Genedefects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 223:1996;224-232.
24. Michael N.L., Chang G., D'Arcy L.A. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J. Virol. 69:1995;4228-4236.
25. Zhang L., Huang Y., Yuan H. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology. 228:1997;340-349.
26. Cornelissen M., Kuiken C., Zorgdrager F. Gross defects in the vpr and vpu genes of HIV type 1 cannot explain the differences in RNA copy number between long-term asymptomatics and progressors. AIDS Res. Hum. Retroviruses. 13:1997;247-252.
27. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearnace rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
28. Wolinsky S.M., Korber B.T., Neumann A.U. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 272:1996;537-542.
29. Lukashov V.V., Kuiken C.L., Goudsmit J. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J. Virol. 69:1995;6911-6916.
30. Harrer T., Harrer E., Kalams S.A. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses. 12:1996;585-592.
31. Harrer T., Harrer E., Kalams S.A. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156:1996;2616-2623.
32. Kalams S.A., Harrer T., Harrer E. HIV-1 specific cytotoxic T lymphocyte and proliferative responses in peripheral blood mononuclear cells (PBMC) of subjects with stable non-progressing HIV-1 infection. XI International Conference on AIDS, Vancouver, July. 1996;. Abstract MoA391.
33. Harrer E., Harrer T., Barbosa P. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J. Infect. Dis. 173:1996;476-479.
34. Klein M.R., VanBaalen C.A., Holwerda A.M. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. M. 181:1995;1365-1372.
35. Kalams S.A., Johnson R.P., Dynan M.J. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cyotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J. Exp. M. 183:1996;1669-1679.
36. +T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
37. +cells correlates with the clinical state of HIV-infected individuals. Proc. Nat. Acad. Sci. USA. 93:1996;13125-13130.
38. +T cells. Science. 270:1995;1811-1815.
39. +T cell-mediated suppression of HIV replication: beta-chemokine-dependent and -independent effects. AIDS Res. Hum. Retroviruses. 13:1997;63-69.
40. +cells: evidence for HLA class1-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:1997;3120-3128.
41. +lymphocyte counts: immunologic and virologic characteristics. J. Infect. Dis. 63:1991;959-965.
42. Baum L.L., Cassutt K.J., Knigge K. HIV-1 gp 120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:1966;2168-2173.
43. Montefiori D.C., Pantaleo G., Fink L.M. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:1996;60-67.
44. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. M. 332:1995;201-208.
45. Bradney A.P., Scheer S., Crawford J.M., Buchbinder S.P., Monetefiori D.C. Neutralization-escape in human immunodeficiency virus type-1-infected long-term nonprogressors. J. Infect. Dis. 19xx;. in press.
46. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science. 272:1996;872-877.
47. Dean M., Carrington M., Winkler C. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273:1996;1856-1862.
48. Michael N.L., Chang G., Louie L.G. The role of viral phenotypes and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature M. 3:1997;338-340.
49. +T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:1997;305-310.
50. Smith M.W., Dean M., Carrington M. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 277:1997;959-965.
51. Magierowska M., Theodorou I., Debrae P. Combined genotypes of CCR5, CCR2, SDF1 and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood. 93:1999;936-941.
52. Winkler C., Modi W., Smith M.W. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Clinic Cohort (SFCC). Science. 279:1998;389-393.
53. McDermott D.H., Zimmerman P.A., Guignard F. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 352:1998;866-870.
54. Carrington M., Nelson G.W., Martin M.P. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science. 283:1999;1748-1752.